StockNews.AI
GILD
StockNews.AI
120 days

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

1. Gilead's Trodelvy combined with Keytruda improves survival in triple-negative breast cancer. 2. Phase 3 study shows significant benefits for mTNBC patients with PD-L1 expression.

2m saved
Insight
Article

FAQ

Why Bullish?

The positive study results for Trodelvy may boost investor confidence and sales potential, similar to past drug approvals enhancing GILD's market performance.

How important is it?

The article discusses a significant study that could increase GILD's product competitiveness and market share in oncology.

Why Long Term?

The findings could lead to increased adoption of Trodelvy, impacting revenues and market position over time, similar to previous successful launches.

Related Companies

MRNAAMGNPFE
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1 (CPS ≥ 10). The.

Related News